

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Pembrolizumab with chemotherapy for treating HER2  
negative advanced gastric or gastro-oesophageal junction  
adenocarcinoma [ID4030]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

|   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No  |

|   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
| Not applicable  |

|  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| Not applicable   |

|  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

No additional stakeholders identified.

**Approved by Associate Director (name):** Janet Robertson

**Date:** 07 July 2023